Novel approach to measuring antibodies against SARS-CoV-2
Current antibody testing strategies are known for their lack of specificity, leading to a large proportion of false positive results. German researchers lead by Prof. Anette-G. Ziegler at Helmholtz Zentrum München developed a novel approach to measuring antibodies against SARS-CoV-2 by defining antibody positivity as a dual-positive response against both the receptor binding domain and nucleocapsid proteins of the virus. This two-step approach allows for more accurate test results, close to a 100% specificity and greater than 95% sensitivity.

As Ziegler and her group have already been conducting a large-scale screening study for pre-symptomatic type 1 diabetes in children, «Fr1da», they could easily and quickly apply this novel testing approach for SARS-CoV-2 antibodies to their existing study infrastructure.

Results of the SARS-CoV-2 antibody screening
Between January 2020 and July 2020, the researchers tested blood samples of almost 12,000 children in Bavaria aged 1 to 18 (who were participants of the Fr1da study) for SARS-CoV-2 dual-antibody positivity. They detected an average antibody frequency of 0.87% from April to July. In comparison to the incidence of virus positive cases reported by the Bavarian Health and Food Safety Authority (in children in Bavaria aged 0 to 18 years from April to July), these antibody frequencies were six-fold higher.

The results showed no differences in sex or age. Almost half (47%) of the antibody-positive children were asymptomatic. In children with virus-positive family members, a third (35%) had antibodies, indicating a higher expected transmission rate in children compared to most previous studies. The regional results within Bavaria revealed substantial geographic differences, with the highest antibody frequency («hot spots») in the south of Bavaria.

The children in this study were also tested for type 1 diabetes autoantibodies, an early marker for pre-symptomatic type 1 diabetes. The researchers found no increase in the frequency of these autoantibodies. This suggests that COVID-19 and type 1 diabetes in childhood are not associated.

Implications for COVID-19 measures «Our study delivered important results revealing the discrepancy between reported virus positive cases and antibody prevalence», says Markus Hippich, who conducted the study as first-author and postdoc at Helmholtz Zentrum München. «As many individuals, in children almost half, do not show COVID-19 symptoms and therefore do not get tested, virus testing only is not a sufficient approach to receive reliable data on the actual virus exposure.»

Prof. Anette-G. Ziegler who lead the study adds: «National antibody screening programs with high specificity and sensitivity could provide countries reliable data to prepare for the future, help them contain the virus spread and monitor the impact of their regional and national containment policies.»

Dashboard
The study results including information on the geographical spread of antibody frequency is available on the study’s dashboard: https://covid-dashboard.fr1da-studie.de/app_direct/covid-dashboard/. The numbers will be updated on a monthly basis.

Limitations
Antibodies against SARS-CoV-2 can take one to four weeks to manifest, which is why these measurements cannot be used for up-to-date prevalence screening. At present, there is no proof that SARS-CoV-2 antibodies lead to immunity. If this is shown to be the case, the results of this screening could provide relevant information on the immunity situation of children in Bavaria.

About the study
The work was supported by grants from the Federal Ministry of Education (BMBF) and the German Center for Diabetes Research (DZD). The Fr1da study is funded by the LifeScience-Stiftung, JDRF, and The Helmsley Charitable Trust.

Learn more about Fr1da: https://www.helmholtz-muenchen.de/en/aktuelles/latest-news/press-information-news/article/47571/index.html

Helmholtz Zentrum München
Helmholtz Zentrum München is a research center with the mission to discover personalized medical solutions for the prevention and therapy of environmentally-induced diseases and promote a healthier society in a rapidly changing world. It investigates important common diseases which develop from the interaction of lifestyle, environmental factors and personal genetic background, focusing particularly on diabetes mellitus, allergies and chronic lung diseases. Helmholtz Zentrum München is headquartered in Neuherberg in the north of Munich and has about 2,500 staff members. It is a member of the Helmholtz Association, the largest scientific organization in Germany with more than 40,000 employees at 19 research centers.

###

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.